Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -48% Improvement Relative Risk c19hcq.org Lyashchenko et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 3,256 patients in the USA (March - June 2020) Higher mortality with HCQ (p<0.000001) Lyashchenko et al., British J. Clinical Pharmaco.., doi:10.1111/bcp.15489 Favors HCQ Favors control
Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City
Lyashchenko et al., British Journal of Clinical Pharmacology, doi:10.1111/bcp.15489
Lyashchenko et al., Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in.., British Journal of Clinical Pharmacology, doi:10.1111/bcp.15489
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective very late stage hospitalized patients in New York during the first wave, showing no significant relationship between HCQ levels and outcomes. Authors note that the patients with data were the sickest patients. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death, 47.7% higher, RR 1.48, p < 0.001, treatment 389 of 1,419 (27.4%), control 341 of 1,837 (18.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lyashchenko et al., 12 Aug 2022, retrospective, USA, peer-reviewed, 6 authors, study period March 2020 - June 2020, average treatment delay 9.5 days.
Contact: mty@cumc.columbia.edu, sc2752@cumc.columbia.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Lyashchenko Alex K (Orcid ID: 0000-0003-0629-0494) Cremers Serge (Orcid ID: 0000-0002-6800-5532) Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City Alex K Lyashchenko1, Yifan Yu2, Donald J McMahon3, Robert Bies2, Michael T Yin3, Serge Cremers2,3 1 Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States of America 2 Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, United States of America 3 Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States of America Corresponding authors: Michael T Yin, MD Associate Professor of Medicine Division of Infectious Diseases Department of Medicine Columbia University Irving Medical Center Email: mty@cumc.columbia.edu Serge Cremers, PharmD, PhD Professor of Pathology and Cell Biology and Medicine Division of Laboratory Medicine Department of Pathology and Cell Biology Columbia University Irving Medical Center This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.15489 This article is protected by copyright. All rights reserved. Email: sc2752@cumc.columbia.edu Running head: PK/PD of Hydroxychloroquine in NYC COVID-19-patients Keywords: COVID-19, Hydroxychloroquine, Pharmacokinetics, Clinical outcome, PK/PD Abstract Aim: To investigate the relationship between systemic exposure to Hydroxychloroquine (HCQ) and its metabolite Desethylhydroxychloroquine (DHCQ) and clinical outcome in severely ill patients treated with a standard oral dose regimen of HCQ during the first wave of COVID-19 in New York City. Methods: We correlated retrospective clinical data with drug exposure prospectively assessed from convenience samples using population pharmacokinetics and Bayesian estimation. Systemic exposure was assessed in 215 patients admitted to ICU or COVID-ward for whom an interleukin-6 level was requested and who were still alive 24h after the last dose of HCQ. Patients received oral HCQ 600 mg bid on day 1 followed by 4 days of 400 mg qd. Results: Fifty-three% of the patients were intubated at 5.4 ± 6.4 days after admission. 26.5% died at an average of 32.2 ± 19.1 days. QTc at admission was 448 ± 34 msec. Systemic exposure to HCQ and DHCQ demonstrated substantial variability. Cumulative HCQ AUC 0-inf =71.4 ± 19.3 h*mg/L and DHCQ AUC0-inf= 56.5 ± 28.3 h*mg/L. Variability in systemic exposure was not clearly explained by renal function, liver function or inflammatory state. In turn, systemic exposure did not correlate with intubation status, survival or QTc prolongation. Conclusion: This study in severely ill patients was not able to find any relationship between systemic exposure to HCQ and DHCQ and clinical outcome at a routine dose regimen and adds to the growing body of evidence that oral HCQ does not alter the course of disease in COVID-19 patients. This article is protected by copyright. All rights reserved. What is already known about this subject - Hydroxychloroquine (HCQ) has been used for the treatment of patients with COVID19 infections, especially during the early phase of the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit